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Although tau is a cytoplasmic protein, it is also found in brain extracellular fluids, e.g., CSF. Recent findings suggest that aggregated tau
can be transferred between cells and extracellular tau aggregates might mediate spread of tau pathology. Despite these data, details of
whether tau is normally released into the brain interstitial fluid (ISF), its concentration in ISF in relation to CSF, and whether ISF tau is
influenced by its aggregation are unknown. To address these issues, we developed a microdialysis technique to analyze monomeric ISF
tau levels within the hippocampus of awake, freelymovingmice.We detected tau in ISF of wild-typemice, suggesting that tau is released
in the absence of neurodegeneration. ISF tau was significantly higher than CSF tau and their concentrations were not significantly
correlated.UsingP301Shuman tau transgenicmice (P301S tgmice),we found that ISF tau is fivefoldhigher than endogenousmurine tau,
consistentwith its elevated levels of expression.However, following theonset of tau aggregation,monomeric ISF taudecreasedmarkedly.
Biochemical analysis demonstrated that soluble tau in brain homogenates decreased along with the deposition of insoluble tau. Tau
fibrils injected into the hippocampus decreased ISF tau, suggesting that extracellular tau is in equilibriumwith extracellular or intracel-
lular tau aggregates. This technique should facilitate further studies of tau secretion, spread of tau pathology, the effects of different
disease states on ISF tau, and the efficacy of experimental treatments.
Introduction
Neurofibrillary tangles (NFTs) consist of fibrillar tau aggregates.
They are a neuropathological hallmark of tauopathies including
Alzheimer’s disease (AD) and forms of frontotemporal dementia
(FTD). Tau is normally a highly soluble, cytoplasmic protein.
However, under pathological conditions, it is hyperphosphory-
lated and aggregates into filamentous structures. The NFT bur-
den and distribution correlate well with cognitive decline in AD
as well as in mouse models of tauopathy (Arriagada et al., 1992;
Bancher et al., 1993; Small and Duff, 2008; Polydoro et al., 2009),
and mutations in tau cause autosomal dominant forms of FTD
(Ballatore et al., 2007). This strongly suggests that tau aggregation
plays a key role in the progression of several neurodegenerative
diseases (Lee et al., 2001).
Although tau is a cytoplasmic protein, it is also present in the
CSF. Thus, tau is probably released from cells as a physiological
process. CSF tau levels change under certain pathological condi-
tions. For example, tau is increased after stroke (Hesse et al.,
2001), markedly increased in prion diseases (Otto et al., 1997),
and increased moderately in AD (Riemenschneider et al., 2003).
Interestingly, however, in forms of FTD caused by taumutations,
CSF tau is not increased (Grossman et al., 2005). Interstitial fluid
(ISF) tau has not been measured in animals, and its relationship
to CSF tau is unknown. In addition to soluble tau that reaches the
extracellular space, recent studies have shown that tau aggregates
can also cross the cell membrane and transfer between cells (Cla-
vaguera et al., 2009; Frost et al., 2009). These findings established
the new concept that extracellular tau might be taken up by cells
and induce intracellular tau accumulation and subsequent
spreading of tau pathology. Therefore the mechanism of tau se-
cretion is of potential relevance to pathogenesis of tauopathies.
Nevertheless, several issues are poorly understood. First, previous
studies have predominantly been performed using mice or cells
overexpressing tau, and there is little evidence that endogenous
tau is physiologically released into the extracellular space. Sec-
ond, it is unclearwhether total tau levels in brain are related to the
concentration of tau in the ISF and CSF. Third, it is unknown
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whether extracellular tau levels in the ISF and CSF change to-
gether in relation to tau pathology. Fourth, no current methods
have been described dynamically assess tau in living/behaving
animals.Microdialysis allows in vivo sampling ofmolecules in the
extracellular space. In this study, we have modified a microdialy-
sis technique previously used to assess ISF A to assess tau from
awake and freely moving mice. We validate this new methodol-
ogy andprovide evidence that tau is released in vivo in the absence
of neurodegeneration, and that ISF tau is significantly higher
than in CSF. ISF tau levels in the presence or absence of tau
aggregates were also investigated using P301S tgmice. Thesemice
showed amarked drop in ISF tau coincidentwith intracellular tau
aggregation, whereas CSF tau increased. Together, these data
suggest that monomeric ISF tau is in equilibrium with either
intracellular or extracellular tau aggregates.
Materials andMethods
Recombinant proteins and antibodies. The longest mouse recombinant
tau isoformmTau40 (432 aa) and the longest human tau isoformhTau40
(441 aa) were produced in the laboratory of EvaMandelkow and used as
standards in the tau ELISA. The mouse monoclonal antibody Tau-5,
which recognizes both human and mouse tau (epitope at residues 218–
225), was from the laboratory of L. Binder (LoPresti et al., 1995; Porzig et
al., 2007). Monoclonal antibodies HJ8.1 and HJ9.3 are mouse monoclo-
nal antibodies raised by immunizing against human tau and mouse tau,
respectively, in tau knock-out mice (The Jackson Laboratory). Both an-
tibodies recognizemouse and human tau onWestern blots, by immuno-
precipitation, and in ELISA assays. HJ9.3 recognizes the microtubule
binding region (MTBR) of tau. The epitope of HJ8.1 has not yet been
defined but is outside of the MTBR. Mouse monoclonal antibody BT-2,
which also recognizes human and mouse tau (epitope at residues 194–
198), was obtained from Pierce.
Animals. All experimental procedures involving animals were per-
formed in accordance with guidelines established by the Animal Studies
Committee at Washington University.
P301S tg mice (line PS19), which overexpress P301S human T34 iso-
form tau (1N4R), have been generated and characterized previously (Yo-
shiyama et al., 2007) and are on a B6C3 background. Age and genetic
background matched nontransgenic mice littermates were used as wild-
type mice. Tau knock-out mice were obtained from The Jackson Labo-
ratory (Dawson et al., 2001). In all experiments, both male and female
were used in this study.
In vitro tau microdialysis. In vitro tau microdialysis using synthetic A
solution (AmericanPeptide) or recombinant tau solutionwas performed
with a fewmodifications fromour previousmethod (Cirrito et al., 2003).
A 2 mm 100 kDa cutoff membrane (CMA12, CMA) was connected to a
microdialysis peristaltic pump with two channels (MAB20; SciPro),
which was operated in a push–pull mode. As a perfusion buffer, 25%
human albumin solution (Baxter) was diluted to 4% with artificial CSF
(aCSF) (1.3 mM CaCl2, 1.2 mM MgSO4, 3 mM KCl, 0.4 mM KH2PO4, 25
mMNaHCO3, and 122 mMNaCl, pH 7.35) on the day of use and filtered
through 0.1 mmembrane.
In vivo tau microdialysis. In vivo microdialysis experiments to assess
brain ISF tau levels from awake and freely moving mice were developed
with modifications of our previously described method (Cirrito et al.,
2003). A guide cannula (CMA12 guide, CMA) was stereotaxically im-
planted in the left hippocampus under isoflurane anesthesia, and ce-
mented. After implantation of the cannula, mice were habituated to
microdialysis cages for 2 d before starting ISF collection. After this recov-
ery period, a CMA12microdialysis probe was inserted through the guide
cannula and microdialysis sample collection was started. To avoid tissue
damage, the experimental window was set from 15 to 48 h after probe
implantation. We have confirmed that within this timeframe ISF tau
concentrations remain constant under constant light conditions. ISF
samples were collected in a refrigerated fraction collector (Scipro) and
analyzed by ELISA at the completion of each experiment. The percentage
recovery in extrapolated zero flow experiments was calculated by divid-
ing tau concentration at each flow rate by the extrapolated actual con-
centration of tau (Menacherry et al., 1992).
Preparation of tau aggregates. The MTBR of recombinant tau was pre-
pared as described previously (Goedert and Jakes, 1990) via exploiting
the heat stability of tau protein followed by cation exchange chromatog-
raphy. Single-use aliquots were stored at 80°C in 10 mM HEPES, pH
7.4, and 100mMNaCl. To induce fibrillization of taumonomer, 8M tau
MTBRwas preincubated at room temperature in 2mM dithiothreitol for
45min followed by incubation at 37°C in 10mMHEPES, pH 7.4, 100mM
NaCl, and 8M heparin for 18 h without agitation. Recombinant MTBR
was then dialyzed in 10,000 molecular weight cutoff Slide-A-Lyzer Dial-
ysis cassettes (Thermo Scientific) against aCSF. Immediately before in-
fusion, MTBR fibrils were sonicated using the Sonicator 3000 (Misonex)
at 1.5 power for 6 2 s pulses.
Tau aggregate infusion. Infusion experiments were performed through
the injection port attached to the guide cannula. PEEK tubing (Small
Parts) was used for infusions and attached to CMA12 guide cannula with
Elmer’s Super-Fast Epoxy Resin. The end of the injection port is located
at the same level as a tip of CMA12 guide cannula, which allows the
infused solution to exit surrounding the CMA12 probe. Before use, the
infusion line was washedwith aCSF and coated by running 0.15%BSA in
aCSF to prevent nonspecific binding of proteins to the inner wall of the
tubing. After collecting baseline tau for 7.5 h at the flow rate of 1.0l/min
from 3.5- to 6-month-old P301S tgmice, a total volume of 2l ofMTBR
fibrils (8 M monomer equivalent) per infusion was delivered into the
hippocampus at 0.07l/min by Hamilton syringe connected to a micro-
dialysis infusion syringe pump (Stoelting). The same volume of aCSFwas
delivered as a vehicle control. Microdialysis fluid was collected for 1.5 h
after the injection was completed, and tau levels were assessed by ELISA.
The presence of MTBR tau aggregates surrounding the probes at the
termination of the experiments was confirmed by performing immuno-
staining with anti-HA antibody.
Tau ELISA. The tau concentration in microdialysis samples were an-
alyzed in a tau sandwich ELISA. Two micrograms of Tau-5 antibody
directed against amino acids 218–225 of tau were coated per well in a
96-well plate (Nunc) and incubated overnight at 4°C. The plate was
blocked with 4% BSA for 60 min at 37°C. Microdialysis samples and
brain extracts and standards diluted with our standard buffer (0.25%
BSA, 300mMTris, 0.05%azide, supplementedwith protease inhibitors in
PBS) were loaded and incubated overnight at 4°C. To assess tau concen-
tration in ISF, the longest mouse tau isoformmTau40 (432 aa) was used
as a standard. Seventy percent formic acid (FA) extracts were neutralized
initially by 1:20 dilution into 1 M Tris phosphate buffer, pH 11, and then
diluted by standard buffer as described previously (Kawarabayashi et al.,
2001). On the next day, biotinylated BT-2 antibody (Pierce) was applied
onto the plate as a detection antibody at a concentration of 0.3g/ml and
incubated for 90 min at 37°C, followed by incubation with streptavidin-
poly-horseradish peroxidase-40 (Fitzgerald) for 90min at room temper-
ature. All assays were developed using Super Slow ELISA TMB (Sigma)
and read on a Bio-Tek FL-600 plate reader at 650 nm. Recombinant
mouse tau was used as a standard. For CSF samples, a 96-well plate with
half area per normal-sized well was used to minimize the volume loaded
per well.
Brain extraction and CSF collection. Mice were perfused with chilled
PBS-heparin, and CSF was collected from the cisterna magna as previ-
ously described (DeMattos et al., 2002). The left hemisphere was col-
lected for immunostaining and fixed overnight in 4% paraformaldehyde
at 4°C and then transferred to 30% sucrose. The right hemisphere was
dissected to isolate the hippocampus for biochemical analysis. Hip-
pocampus was kept at80°C until analyzed. Hippocampus was weight
and homogenized in RAB buffer [100 mM MES, 1 mM EDTA, 0.5 mM
MgSO4, 750 mM NaCl, 20 mM NaF, 1 mM Na3VO4, supplemented by
protease inhibitor (Complete, Roche) and phosphatase inhibitor
(PhosSTOP,Roche)]. The samples were centrifuged at 50,000 g for 20
min at 4°C. The supernatants were collected as RAB soluble fractions.
The pellets were resuspended in RIPA [150 mM NaCl, 50 mM Tris, 0.5%
deoxycholic acid, 1% Triton X-100, 0.5% SDS–25 mM EDTA, pH 8.0,
supplemented by protease inhibitor (Complete, Roche) and phosphatase
inhibitor (PhosSTOP, Roche)] and centrifuged at 50,000 g for 20 min
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at 4°C. The supernatants were collected as RIPA soluble fractions. The
pellets were resuspended in 70% formic acid and centrifuged at 50,000
g for 20 min at 4°C. The supernatants were collected as 70% formic acid
fractions. All fractions were used for immunoblot analysis.
Immunoblot analysis. Fractionated brain extracts were dissolved in a
sample buffer containing 2% -mercaptoethanol and 2% SDS. Before
applying sample buffer, 70% formic acid fractions were neutralized by
diluting 1:3 with 1:1 mixture of 10N NaOH and neutralization buffer (1
mol/L Tris base; 0.5mol/LNaH4PO4) as described previously (Clinton et
al., 2010). Proteins were separated by reducing 4–12% Bis-Tris mini-gel
(Invitrogen), transferred to PVDF membrane, and incubated with BT-2
antibody (Pierce) or anti-actin (Sigma), followed by HRP-conjugated
anti mouse antibody (GE Healthcare Pharmacia Biotech). Bands were
visualized with Lumigen-TMA6 (GE Healthcare).
Immunoprecipitation and immunoblot analysis. Hippocampal micro-
dialysis samples were collected at 1.0 l/min for 15 h from P301S tau
transgenic mouse and wild-type mice. ISF was immunoprecipitated by
Dynabeads (Invitrogen) coatedwithHJ8.1 orHJ9.3 tau antibody accord-
ing to themanufacturer’s instructions. Precipitated fractionswere loaded
on a reducing 4–12% Bis-Tris mini-gel (Invitrogen) and transferred to
nitrocellulosemembrane. Biotinylated BT-2 antibody (Pierce) and Poly-
HRP-conjugated streptavidin (ThermoScientific) were used to eliminate
the interference of precipitated antibodies.
Statistical analysis. Data in figures represent mean  SEM. All statis-
tical analysis was performed using Prism version 5.04 for Windows
(GraphPad). Differences in ISF tau levels were analyzed using a one-way
ANOVA followed by post hoc test.
Results
Development and validation of a tau microdialysis technique
in wild-type and P301S tau transgenic mice
To determine whether we could measure recombinant tau via
microdialysis in vitro, probes with 100 kDa cutoff membranes
were used. Higher molecular weight cutoff membrane sizes usu-
ally cause fluid loss from the probe. Generally, this phenomenon
is caused by hydrostatic pressure created inside of the probe
(Trickler and Miller, 2003). To minimize the fluid loss from mi-
crodialysis probes, we increased the osmotic pressure of the per-
fusion buffer by using a 4% albumin solution.We also operated a
peristaltic pump in a push–pull mode to prevent pressure from
being created. These technical changes from our prior method to
assess A (Cirrito et al., 2003) were first tested by performing in
vitro A microdialysis using 100 kDa cutoff probes. We found
that 4%albumin increased themeasuredA concentration in the
dialysate by fourfold compared to 0.15% BSA, which we nor-
mally use for A microdialysis (data not shown). The use of a
push–pull pump also improved the recovery by 1.6-fold com-
pared to a push pump. These technical improvements also al-
lowed us to collect recombinant tau through 100 kDa cutoff
microdialysis probes in vitro (data not shown). The ISF tau being
measured is soluble monomeric tau due to the cutoff size of the
microdialysis membrane.
We next evaluated the microdialysis technique in vivo. We
first addressed whether tau is normally present in the brain ISF in
the absence of neurodegeneration. To address this issue, in vivo
tau microdialysis was initiated in both wild-type mice and in
3-month-old P301S tg mice, at an age before the appearance of
insoluble tau and neurodegeneration. In this study, we focused
our investigations on hippocampus, which is one of the regions
affected by tau pathology relatively early during aging (Braak and
Braak, 1997; Duyckaerts and Hauw, 1997) as well as in different
tauopathies. The mice were implanted with microdialysis probes
and ISF was sampled. The tau concentration in the collected di-
alysate was quantified by Tau-5/BT-2 ELISA. This ELISA recog-
nizes mouse tau and human tau equivalently, which allows us to
quantify total tau levels in ISF (Fig. 1A).
Interestingly, we were able to detect monomeric tau in ISF
from both P301S tg mice and wild-type littermates measured as
frequently as every hour. We determined the in vivo absolute
concentration of monomeric ISF tau by the extrapolated zero
flow method (Cirrito et al., 2003; Kim et al., 2009). In this
method, we varied the flow rate of microdialysis perfusion buffer
(Fig. 1B). The relative recovery of tau and other molecules is
inversely related to the flow rate. Therefore the concentration of
tau recovered bymicrodialysis, i.e., exchangeable tau (e-tau), can
be determined by extrapolating the recovery curve back to theo-
retical zero flow rate, which represents the estimated in vivo con-
centration of ISF tau. Utilizing this method, the monomeric ISF
e-tau concentration is 44.9  9.4 ng/ml in 3-month-old wild-
type mice and 248.8 54.2 ng/ml in P301S tg mice (Fig. 1B,C).
This fivefold difference is consistent with the expression level of
human tau being approximately fivefold higher in P301S tg mice
than in endogenous murine tau (Yoshiyama et al., 2007). The
concentrations of e-tau in the ISF of wild-typemice are10-fold
higher than the levels found in mouse CSF (Fig. 1D). Given that
bothwild-type and P301Smice showno evidence of neurodegen-
eration at this age, and that we have previously shown that there
is no significant cell death caused by microdialysis probe inser-
tion (Cirrito et al., 2003), these data suggest that tau is normally
Figure 1. e-tau in 3-month-old wild-typemice and P301S tau tgmice. A, Tau-5/BT-2 ELISA
recognizes recombinant human tau andmouse tau equivalently.n4.B, At varying flow rates
of the microdialysis perfusion buffer from 0.35l/min to 1.5l/min, e-tau was quantified by
ELISA in the hippocampus in wild-type (WT, n 12) and P301S tg (P301S tg, n 7) mice. C,
The mean e-tau levels were calculated by the zero flowmethod. ***p 0.0001 by unpaired t
test.D, ISF (n 13) and CSF (n 8) tau levels weremeasured in 3-month-oldwild-typemice.
**p 0.01 by unpaired t test. E, e-tau levels was determined in 3-month-old wild-type mice
(WT, n 5) and tau knock-out mice (Tau KO, n 5).
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released from cells into the extracellular space of brain under
physiological conditions. Further, the specificity of our assay was
confirmed by performing microdialysis on tau knock-out mice.
There is no detectable tau in these mice at any time examined
(Fig. 1E).
Full-length tau is present in ISF
To determine the major tau species in ISF recovered by the mi-
crodialysis probe, we immunoprecipitated tau from the ISF sam-
ples of both wild-type mice and P301S tg mice using tau
antibodies recognizing both mouse and human tau. We chose to
use two anti-tau monoclonal antibodies that worked well in im-
munoprecipitation assays as the amount ofmonomeric tau in ISF
is still relatively low. Following immunoprecipitation, we ana-
lyzed tau by immunoblot. Endogenous murine tau isoforms mi-
grate at 48–62 kDa (Takuma et al., 2003). In wild-type brain
lysate, tau appeared in four separate bands on SDS-PAGE (Fig.
2A). The most abundant species in wild-type mice migrated at
48 kDa. In P301S tg mice brain, in addition to the four endog-
enous murine tau bands, overexpressed human 1N4R tau was
observed as an intense bandmigrating at 55 kDa as well as a 39
kDa band, which may represent a tau degradation product.
In contrast to total brain lysates, upon immunoprecipitation,
a single tau band was detected with antibody HJ9.3 recognizing
the MTBR region of tau in ISF from wild-type mice (Fig. 2B).
This band corresponded to the largest isoform 2N4R observed in
mouse brain lysate. In ISF of P301S tgmice, a human-specific tau
band was coprecipitated with the aforementioned mouse tau
band and was slightly lower in molecular weight (Fig. 2B). These
two bands were also precipitated by another mouse monoclonal
antibody raised against tau HJ8.1 (Fig. 2C). These data suggested
that the major species in ISF that we are assessing by ELISA is
likely full-length monomeric tau.
Monomeric ISF Tau decreases in P301S Tau transgenic but
not wild-type mice over time
We hypothesized that monomeric ISF tau levels would be influ-
enced by the presence of tau aggregates. To test this hypothesis,
we assessed monomeric ISF tau in both P301S tg and wild-type
mice at different ages. P301S tg mice begin to accumulate fila-
mentous tau at 6 months of age, which then progressively ac-
cumulates in an age-dependentmanner (Yoshiyama et al., 2007).
The in vivo concentration of monomeric ISF tau in 3-, 6-, and
12-month-old P301S tg mice was determined by the zero flow
method (Fig. 3A). ISF tau decreased in an age-dependentmanner
(Fig. 3A,C). P301S tg mice at both 3 and 6 months have tau
concentrations of 248.8 54.2 and 227.4 36.8 ng/ml, respec-
tively. In contrast, monomeric ISF tau levels dropped by 70%
to 72.3  28.0 ng/ml at 12 months of age. Monomeric ISF tau
levels were alsomeasured in 3 and 12- to 15-month-oldwild-type
mice (Fig. 3B). No age-dependent change of monomeric ISF tau
levels in wild-type mice was detected (Fig. 3B,C). We also com-
pared the percentage recovery of monomeric ISF tau at each flow
rate at all ages of P301S tg mice. There was no change in the
percentage recovery, ruling this out as an explanation for the
drop in monomeric ISF tau in the P301S tg mice (Fig. 3D). To-
gether, these data suggest that the dramatic drop in monomeric
ISF tau levels with age in P301S tg mice is linked to tau aggregate
formation and accumulation.
CSF tau in P301S human tau transgenic mice
Tau is present in human CSF (Vandermeeren et al., 1993; Perrin
et al., 2009). Thus, we determined the tau concentrations in CSF
Figure 2. Full-length tau is present in ISF of wild-type and P301S tg mice. A, Hippocampal
lysates from Tau KO (KO), wild-type (WT), and P301S tg (P301S tg) mice were analyzed by
immunoblot with the anti-tau antibody BT-2 or anti-actin antibody. Thirteen micrograms of
protein were loaded per well. Four bands corresponding to endogenous murine tau and one
band corresponding to human tau are indicated as white circles and a black circle, respectively.
There is also a 39 kDa band representing a form of human tau in the P301S tg hippocampal
lysate. Thismay represent a tau degradation product. ISF tau fromwild-type (WT) and P301S tg
(P301S tg)micewas immunoprecipitated by anti-taumonoclonal antibodies HJ9.3 (B) or HJ8.1
(C) and analyzed by immunoblot. The bandswere visualized by biotinylated BT-2 antibody. The
gray and black arrows indicate endogenous murine tau and human tau, respectively.
Figure 3. e-tau in P301S tg mice and wild-type mice at different ages. A, Zero flow experi-
ments were performed in 3- (3 mo, n 12), 6- (6 mo, n 12), and 12- (12 mo, n 8)
month-old P301S tg mice. Tau levels at each flow rate were quantified by ELISA. B, Zero flow
experimentswere performed in 3- (3mo,n 12) and 12- to 15- (12–15mo,n 6)month-old
wild-type mice. Tau levels at each flow rate were quantified by ELISA. C, The mean e-tau was
assessed in 3- (3mo, n 12), 6- (6mo, n 8), and 12- (12 mo, n 8) month-old P301S tg
mice and 3- (3mo,n 12) and 12- to 15- (12–15mo,n 6)month-oldwild-typemice by the
zero flow method. *p 0.05, **p 0.01. D, The percentage recovery of tau from P301S tg
mice was calculated and plotted against flow rates. There is no difference in the percentage
recovery between groups.
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of P301S tg mice. In contrast to ISF, we found that CSF tau in
P301S tg mice increased in an age-dependent manner (Fig. 4A).
CSF tauwas 24.9 6.4 and 36.5 12.4 ng/ml in 3- and 6-month-
old P301S tg mice, respectively, whereas it was 48.2 3.7 ng/ml
in 12-month-old P301S tg mice. In 3-month-old P301S tg mice,
CSF tau was10% of tau measured in ISF.
Since there is no diffusion barrier between ISF and CSF, we
wondered whether the increase in CSF tau correlated with
changes in ISF tau levels. We assessed hippocampal ISF and CSF
tau in individual mice. If these two pools were directly related to
each other, a negative correlation would be expected. However
there was no correlation between ISF and CSF tau, suggesting
independent regulation (Fig. 4B).
Age-dependent decrease of total brain soluble tau in P301S
tau transgenic mice
P301S tg mice develop tau pathology in an age-dependent man-
ner (Yoshiyama et al., 2007). The decrease ofmonomeric ISF tau,
along with the presence of tau pathology, led us to hypothesize
that tau aggregates decrease soluble tau. To determine whether
soluble tau is decreased with age in P301S tg mice, hippocampal
tissue was sequentially extracted with RAB and RIPA buffer, fol-
lowed by 70% FA solubilization, and analyzed by immunoblot.
In wild-type mice, endogenous murine tau was collected ex-
clusively in the first two fractions RAB and RIPA, and there was
no detectable tau in the 70% FA soluble fraction (Fig. 5A). Hu-
man and mouse tau was also observed in the RAB and RIPA
fractions in 3- and 6-month-old P301S tg mice with no tau pres-
ent in the insoluble fraction by immunoblot. In contrast, in 12-
month-old P301S tg mice, there was a decrease of human tau in
the RAB and RIPA fractions. (Fig. 5A).
To assess tau levels in amore quantitative fashion, tau levels in
each fraction were also measured by ELISA (Fig. 5B–D). Consis-
tent with immunoblot analysis, tau levels in the RAB fraction
were decreased by 32% in 6-month-old mice and by 52% in
12-month-old mice compared to 3-month-old P301S tg mice.
Tau levels in the RIPA fraction were also decreased by 38% in
12-month-old P301S tg mice compared to 3-month-old mice. In
contrast, insoluble tau in 70% formic acid fractionswas increased
by 3.5-fold in 12-month-old P301S tg mice. These data suggest
that the insoluble brain tau results in a decrease in brain soluble
tau, which corresponds to a reduction of ISF tau.
Tau aggregates decrease monomeric ISF tau in vivo
A previous study with cultured cells suggested that tau aggregates
are released into the extracellular space (Frost et al., 2009). Thus
we hypothesized that extracellular tau aggregates, if present,
might decrease monomeric ISF tau. We prepared tau aggregates
in vitro and injected them into the brain while simultaneously
measuring soluble monomeric ISF tau levels. We used a form of
truncated tau that comprises the repeat domain of the MTBR.
The repeat domain of tau readily forms filaments because it lacks
the N- and C-terminal flanking domains and exposes the core
with high-propensity (von Bergen et al., 2000), and thusMTBR
can seed fibril formation of tau monomer in vitro (Frost et al.,
2009). BecauseMTBR tau aggregates lack the epitopes recognized
by the BT-2 and Tau-5 antibodies used in our tau ELISA, this
injection strategy allowed specific detection of endogenous mo-
nomeric ISF tau (Fig. 6A).
After collecting baseline monomeric ISF tau, MTBR tau ag-
gregates or vehicle were infused around the microdialysis probe
through an injection port attached to microdialysis guide can-
nula. The monomeric ISF tau concentration before and after in-
Figure 4. CSF tau concentration in P301S tg mice. A, CSF tau levels in 3- (3mo, n 10), 6-
(6mo,n5), and12- (12mo,n8)month-old P301S tgmicewere quantified by ELISA. *p
0.05. B, Relationship between ISF tau and CSF tau in P301S tg mice. There is no significant
correlation between ISF tau and CSF tau.
Figure 5. Hippocampal soluble and insoluble tau levels in P301S tgmice. A, The hippocam-
pus from P301S tg (P301S tg), wild-type (WT), and Tau KO (Tau KO) mice were sequentially
extracted by RAB, RIPA, 70% FA, and extracted proteins were analyzed by immunoblot with
BT-2 (anti-tau) or anti-actin antibody as a control. Black and gray arrows indicate human tau
andendogenousmurine tau, respectively. Tau levels in RAB fractions (B), RIPA fractions (C), and
70% formic acid fractions (D) were quantified by ELISA. n 5–8, **p 0.01, ***p 0.001.
Figure6. Tau aggregates induce an acute decrease of ISF tau levels in 3-month-old P301S tg
mice. A, Tau aggregates containing theMTBR. MTBR is not recognized by tau antibodies (BT-2,
Tau-5) used in ELISA. B, Relative e-tau levels after injection of vehicle (n 3) or MTBR aggre-
gates (n 4) in P301S tg mice were measured by ELISA. *p 0.05.
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jection was measured by ELISA. The injection of tau aggregates
reduced ISF tau levels by 30% compared to baseline mono-
meric ISF tau levels (Fig. 6B). In contrast, vehicle infusion did
not alter monomeric ISF tau levels. When infused in ISF of wild-
type mice, MTBR aggregates did not change endogenous murine
tau levels, suggesting that P301S tau with higher aggregation po-
tential is preferentially sequestered by aggregates (data not
shown). Together, these data suggested that extracellular tau ag-
gregates, if present, can decrease soluble monomeric ISF tau.
Discussion
We have demonstrated that monomeric tau is normally present
in the brain ISF and can be measured on an hourly basis using
microdialysis. Its levels in ISF are much higher than in CSF and
levels in ISF parallel the levels of tau in brain homogenates. Uti-
lizing P301S tg mice, we found that monomeric ISF tau is
dramatically decreased following the onset of tau aggregation.
Supporting the idea that the decrease in ISF tau is due to an
equilibrium between either intracellular or extracellular tau ag-
gregates, infusions of aggregated tau result in a rapid decrease in
monomeric ISF tau.
We provide direct evidence that monomeric tau is present in
ISF of wild-type mice, even in the absence of neurodegeneration.
Even though tau lacks a signal sequence, its release into the extra-
cellular space appears to be a normal process. These data are
consistent with the previous observation that tau is present in
CSF of humans without neurodegeneration.
The level of monomeric tau present in the ISF was paralleled
the level of tau protein in the brain. Tau protein is approximately
fivefold higher in P301S tg mice brain
than in wild-type littermates, and similar
differences between P301S tg mice and
wild-type mice were found in ISF. This is
important because it suggests that the lev-
els of intracellular and extracellular tau
are related. We explored the form of tau
present in ISF by immunoprecipitation. It
was observed that tau species, which ap-
pear to correspond to full-length tau, were
present in ISF of both wild-type mice and
P301S tg mice. Tau was immunoprecipi-
tated with two different antibodies re-
cognizing different regions of tau and
migrated at molecular weights consistent
with them being full-length tau. Most re-
gions of tau also have been identified in
human CSF using mass spectrometry as
well as the media of cultured cells (Porte-
lius et al., 2008; Kim et al., 2010a). Immu-
noprecipitated ISF tau from wild-type
mice was higher in molecular weight than
the most abundant tau isoform present in
brain lysates. This suggests that there
might be a particular isoform or post-
translationally modified form of tau that
is released from cells in a regulated fash-
ion. Recent work also indicated that re-
lease of tau depends on the N-terminal
half of tau (Kim et al., 2010b).
The mechanism whereby tau is re-
leased into the extracellular space is still
unknown. Besides tau, there are increas-
ing numbers of intracellular proteins that
lack ER signal sequences but reach the ex-
tracellular spaces via an unconventional secretion pathway
(Nickel, 2010). Even though tau lacks a transmembrane or obvi-
ous secretion signal sequence, some tau has been observed in
membranous compartments such as the Golgi body, plasma
membranes, and mitochondria, which could be linked to secre-
tion (Jung et al., 1993; Brandt et al., 1995; Farah et al., 2006).
Exosome-mediated secretion, which has been suggested as a
mechanism of -synuclein secretion, could also play a role (Em-
manouilidou et al., 2010). While it is certainly possible that tau
dimers, trimers, oligomers, or even tau exosomes exist in ISF, our
current method would not allow for the direct assessment of
these structure, since the dialysis probe cutoff is 100 kDa. Recent
findings provide strong evidence that soluble tau, possibly an
oligomer, can cause neuronal dysfunction independent of NFTs
(Oddo et al., 2006; Thies and Mandelkow, 2007; de Calignon et
al., 2010;Hoover et al., 2010). For example, synaptic failure in the
P301S tg mice occurs before tangle formation (Yoshiyama et al.,
2007). In other studies, cognitive dysfunction of these mice was
improved by suppressing tau expression despite ongoing accu-
mulation of NFTs, suggesting that some form of soluble tau may
be critical in neurodegeneration (Santacruz et al., 2005; Mocanu
et al., 2008). Other studies suggest that soluble, nonaggregated
tau is a common mediator of neuronal injury due to both exci-
totoxicity and APP/A (Roberson et al., 2007, 2011; Ittner et al.,
2010). This has led to the idea that suppression of tau levels as
therapy. Taumicrodialysis provides a dynamic in vivomethod to
assess pharmacodynamic effects of treatments on tau lowering.
While extracellular taumay generally reflect levels of intracellular
Figure 7. Proposed diagram of tau release in the presence or absence of tau aggregates. A, Tau is released from neurons under
normal conditions. B, Once tau aggregates form inside (1) or potentially outside (2) of cells, they can sequester intracellular and
extracellular soluble tau and lower the level of monomeric tau in the extracellular space.
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tau, the potential role of extracellular tau in any of the toxic or
other properties of tau, if any, is unknown. As some studies have
reported a cytotoxic effect of extracellular tau when it is added to
culture medium (Go´mez-Ramos et al., 2006, 2008), it will be
important to examine the effect of soluble extracellular tau on
neuronal dysfunction.
Intriguingly, recent studies have shown that propagation of
tau aggregation from the outside to the inside of the cell occurs in
vivo and in cell culture models. This could explain the vulnera-
bility of specific networks in tauopathies and other neurodegen-
erative diseases (Frost and Diamond, 2010). It is noteworthy that
anti-tau immunotherapy has beneficial effects in mouse models
of tauopathy (Asuni et al., 2007; Sigurdsson, 2009; Boutajangout
et al., 2010). While the mechanism underlying tau immunother-
apy has not yet been clarified, if extracellular tau is the target
molecule, taumicrodialysismay provide an opportunity to better
assess therapeutic mechanisms.
We found that ISF tau levels dramatically decrease from 6 to
12 months of age in P301S tg mice. This change with age was not
seen in the wild-type mice, suggesting that it is disease related. It
seemsmost likely that ISF tau is in equilibriumwith extracellular,
intracellular tau aggregates, or both. Indeed, we observed that
soluble tau from brain homogenates of P301S tg mice was de-
creased in parallel with the deposition of insoluble tau. We favor
a sequestration model. This was reported in another mouse
model (Deters et al., 2008). Further, using regulatable tau trans-
genic mouse models, a dynamic equilibrium between soluble tau
and insoluble tau was observed (Sydow and Mandelkow, 2010;
Sydow et al., 2011). Increased clearance could also account for the
decrease in ISF tau, which we will test in future studies.
We observed that exogenously administrated tau aggregates
quickly reduce ISF tau levels. Tau aggregates in the extracellular
space could lead to decrease ISF tau even in relatively young
P301S mice. In contrast to ISF tau, CSF tau increased with age in
P301S tg mice. One possibility is that CSF tau may increase with
neurodegeneration.We have measured ISF tau in the hippocam-
pus of these aged mice, where many aggregates form and where a
similar reduction in ISF tau was observed. Thus, it is possible that
hippocampal aggregates influence ISF tau locally, whereas CSF
tau levels reflect mean changes in total extracellular tau in the
CNS. Further, oligomers are not measurable in ISF with this mi-
crodialysismembrane and could result in an apparent decrease in
older P301S tg mice. This is reminiscent of our previous finding
that A in hippocampal ISF of APP transgenic mice is also not
correlatedwith A in CSF (Cirrito et al., 2003). Further, ISF tau is
significantly higher than CSF levels. Because tau is a large protein
that may be cleared prominently by cellular uptake, local degra-
dation, and perivascular drainage (Weller et al., 2008), most of it
may never reach the CSF via bulk flow or diffusion.
Herein, we propose amodel to explain the dynamics of ISF tau
(Fig. 7). In the absence of tau aggregates, tau is released into ISF
via undefined mechanisms. In contrast, in the presence of tau
aggregates, tau is sequestered within the cells, which leads to the
decrease in ISF tau. Once tau aggregates are released from cells,
they can also be sequestered extracellularly, decreasing ISF tau
levels.
In summary, our microdialysis method enabled the measure-
ment of extracellular tau from both wild-type and human tau
transgenic mice. These data provide a link between tau metabo-
lism, ISF tau, and tau aggregation, and this approach provides an
in vivo tool to assess tau-mediated pathogenesis and treatments
that influence tau levels dynamically in vivo. This method may
also provide an important way to investigate the role of extracel-
lular tau on the spreading of tau pathology and neuronal
dysfunction.
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